Literature DB >> 8749885

Conventional antipsychotic medications for schizophrenia.

L B Dixon1, A F Lehman, J Levine.   

Abstract

This article reviews the existing evidence for the efficacy and effectiveness of conventional antipsychotic medications in the treatment of schizophrenia. Among the issues reviewed are their efficacy for acute symptom episodes and for long-term maintenance therapy, differential efficacy among medications, the gap between research-based efficacy rates and effectiveness rates in practice, dosing strategies, and the treatment of first-episode cases. Evidence for efficacy is overwhelming for reduction of positive symptoms but quite limited for other outcomes. Effectiveness in practice may be substantially less than efficacy in clinical trials, perhaps owing to patient heterogeneity, prescribing practices, and noncompliance. First-episode patients should be treated with antipsychotic medication, but perhaps at lower dosages, with consideration of a gradual decrease or discontinuation at 6 months to 1 year.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8749885     DOI: 10.1093/schbul/21.4.567

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  24 in total

1.  Effect of antipsychotics on succinate dehydrogenase and cytochrome oxidase activities in rat brain.

Authors:  Emilio L Streck; Gislaine T Rezin; Luciana M Barbosa; Lara C Assis; Eliane Grandi; João Quevedo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-08-03       Impact factor: 3.000

2.  Socio-demographic correlates of treatment response among patients with schizophrenia in a tertiary hospital in South-East Nigeria.

Authors:  Mark S Ezeme; Richard Uwakwe; Appolos C Ndukuba; Monday N Igwe; Paul C Odinka; Kennedy Amadi; Nichodemus O Obayi
Journal:  Afr Health Sci       Date:  2016-12       Impact factor: 0.927

Review 3.  Antipsychotic medication for early episode schizophrenia.

Authors:  John Bola; Dennis Kao; Haluk Soydan
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

4.  William T. Carpenter Jr: 35 years of clinical trials.

Authors:  Robert W Buchanan
Journal:  Schizophr Bull       Date:  2014-03       Impact factor: 9.306

Review 5.  Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety.

Authors:  Matthew T Morris; Sandip P Tarpada
Journal:  Psychopharmacol Bull       Date:  2017-05-15

6.  Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.

Authors:  S H Hamilton; D A Revicki; E T Edgell; L A Genduso; G Tollefson
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981

Review 7.  Improving treatment for persons with schizophrenia.

Authors:  A F Lehman
Journal:  Psychiatr Q       Date:  1999

Review 8.  Amisulpride: a review of its use in the management of schizophrenia.

Authors:  M P Curran; C M Perry
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 9.  The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

Authors:  Robert W Buchanan; Julie Kreyenbuhl; Deanna L Kelly; Jason M Noel; Douglas L Boggs; Bernard A Fischer; Seth Himelhoch; Beverly Fang; Eunice Peterson; Patrick R Aquino; William Keller
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

Review 10.  The history of community mental health treatment and rehabilitation for persons with severe mental illness.

Authors:  Robert E Drake; Alan I Green; Kim T Mueser; Howard H Goldman
Journal:  Community Ment Health J       Date:  2003-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.